ACHYUT HEALTHCARE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 54 INR | 0.00% |
|
0.00% | -6.90% |
| 05-28 | Achyut Healthcare Turns to Profit in Fiscal Q4 | MT |
| 01-16 | Achyut Healthcare Limited announced that it has received INR 157.248 million in funding | CI |
| Sales 2022 | 40.49M 485K 666K | Sales 2023 | 26.96M 323K 443K | Capitalization | 511M 6.12M 8.4M |
|---|---|---|---|---|---|
| Net income 2022 | - 0 0 | Net income 2023 | 2M 23.94K 32.88K | EV / Sales 2022 | 2.05 x |
| Net cash position 2022 | 55.61M 666K 914K | Net cash position 2023 | 86.91M 1.04M 1.43M | EV / Sales 2023 | 15.7 x |
| P/E ratio 2022 |
344
x | P/E ratio 2023 |
221
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 19.71% |
More Fundamentals
* Assessed data
More news
| Current month | +13.14% | ||
| 1 month | +14.89% | ||
| 3 months | +25.29% | ||
| 6 months | -1.82% | ||
| Current year | -6.90% |
1 week
54.00
54.00
1 month
47.7355.10
Current year
40.2358.50
1 year
34.3960.79
3 years
10.0060.79
5 years
10.0060.79
10 years
10.0060.79
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 54 | 21-01-27 | |
Drashti Unadkat
CMP | Compliance Officer | - | 23-04-13 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 21-08-31 | |
| Director/Board Member | 35 | 21-08-31 | |
| Director/Board Member | 27 | 21-10-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-10 | 54 | 0.00% | 2,250 |
| 24-06-07 | 54 | +12.50% | 2,250 |
Delayed Quote Bombay S.E., June 10, 2024 at 06:00 am
More quotes
Achyut Healthcare Limited is an India-based pharmaceutical trading company. The Company is focused on dealing in active pharmaceutical ingredients (API), pharmaceutical products, and medical devices. The Company is engaged in the business of pharmaceutical formulations in the forms of tablets, capsules, oral liquid and injectable. The Company is engaged in trading of Cenzure, Arpimune, Azathioprine IP, Everomimus, Mycophenolate Mofetil USP, Mycophenolate Sodium USP, Sirolimus, Tacrolimus USP, Infrared thermometer, Ascorbic Acid Coated Vitamin C, Calcium carbonate oyster, Cellulose acetate Phthalate, Chlorthalidone IP, Cross Carmalose Sod IP/USP, DI Basic Calcium Phosphate IP, DI Ethyl Phthlate, Diltiazem Hydrochloride IP, Easy Coat Fc Titanium Dioxide, Escitalopram IP, Escitalopram Oxalate, Favipiravir among many other products.
Sector
Pharmaceuticals
Calendar
2024-11-10
- Q2 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -6.90% | 10.88M | |
| +41.96% | 630B | |
| -7.15% | 350B | |
| +18.77% | 328B | |
| +8.79% | 298B | |
| +18.02% | 246B | |
| +1.27% | 225B | |
| +11.95% | 218B | |
| +3.68% | 160B | |
| -4.38% | 156B |
- Stock Market
- Equities
- 543499 Stock
